Member Info for Prion25

In vivo results are encouraging looking forward to the published data

I see Ratko mentioned in Refs 50

Djukanović, R. et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am. J. Respir. Crit. Care Med 190, 145–154 (2014).

The Proactiveinvestor article clearly states :

UBS is buoyant about Ceres' future, underpinned by management's confidence in securing more deals in 2024, and sees another fundraise as "unlikely".

Https://www.bbc.com/news/world-australia-67870595.amp

Not forgetting glioblastoma project pipeline

OBD conducted a Retrospective study comparing high risk positive pCa, negative pCa and asymptomatic patients from a PROSTAGRAM clinical study and control samples were supplied by Imperial The PSE test was matched against the PSA and other results and we all know the outcome of this the PSE outperformed PSA In my opinion other than perhaps it being a small population study it does not require protracted large scale Clinical trials for high risk groups when used along side of the PSA test They acknowledge that for population screening then further Prospective trials will be required this data would evolve if PSE was used along side of PSA routinely until it replaces the PSA once validated

Broker RBC got it wrong then ? Underperform 150

Https://www.deltaww.com/en-US/news/38905

Https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html

Apologies if already posted , interesting we in the right place at the right time GLA

RBC cuts Ceres Power to 'underperform' (sector perform) - price target 150 (600) pence

Https://pmwcintl.com/

Any delegates sent from Avacta ?

InvestingGenius

Thank you for your useful contribution

Thenorseman

“Dunga”

I have done my own research and the licences have expired ,What is the cost and process to renew licences to drill the various leads ??

Thali Production Sharing Contract (PSC) in Cameroon, which covers an area of 119.2 km² in the Rio del Rey basin. Tower Resources holds a 100% interest in this licence and is the operator. The licence was extended for one year in September 2020 and is valid until September 2021. The company plans to drill the Njonji-3 well in 2021, subject to rig availability and financing.

Algoa-Gamtoos Exploration Right in South Africa, which covers an area of 11,800 km² offshore the southern coast of South Africa, adjacent to the Baviaanskloof World Heritage Site. Tower Resources holds a 50% interest in this licence and is the operator. The licence was granted in December 2014 and is valid for six years. The company has identified several prospects and leads in the licence area, including the Algoa Deep and Gamtoos prospects.

Namibia PEL 96 in Namibia, which covers an area of 23,297 km² in the Walvis Basin and Dolphin Graben offshore Namibia. Tower Resources holds a 30% interest in this licence and is not the operator. The licence was granted in June 2015 and is valid for four years, with an option to extend for two more years. The company has identified several prospects and leads in the licence area, including the Alpha and Gamma prospects.

Https://www.factmr.com/report/doxorubicin-market

Https://www.msn.com/en-gb/health/medical/how-to-understand-ohio-s-white-lung-syndrome-pneumonia-outbreak-and-why-it-s-not-linked-to-china/ar-AA1kVOvW?ocid=msedgntp&pc=HCTS&cvid=06de05dd521d497098b7ab7d4c6a3089&ei=41

Https://www.sharecast.com/

Large 194 k Buy at cop will it be enough?

Toltorisk

You are correct so many negatives affecting the world markets atm .An existential threat to mankind and the planet is climate change and to achieve net zero could be our only salvation If you believe( and our politicians )in climate change then there is an urgent an over riding need for technologies such as Ceres and ITM to invest and save our future generations

Https://www.msn.com/en-gb/news/other/my-young-cancer-patient-refused-all-treatment-after-her-death-i-found-out-why/ar-AA1ki29B?ocid=msedgntp&pc=HCTS&cvid=46bb35c8727b4960b82b5b5397f853eb&ei=41

Https://find-and-update.company-information.service.gov.uk/company/06108621/officers

Most have resigned?

@dugwalker

As I said the first time yesterday evening I became aware of the Transform trial yesterday evening read the BMI study as part of my own research and concluded the intend to investigate using mpMRI as a primary screening tool independent of PSA This paper was published in August 2023 and PSE was launched in September 2023 I went onto say that in this early BMI study PSE was may have not considered as it had not been launched or validated at the start of BMI study .That’s not to say PSE will not be considered since it’s launch as the most powerful diagnostic tool we have available even as you said probably outperforming MRI and ultrasound .Other technologies such as AI reading biopsy slides may be under consideration for Transform to speed up diagnosis and accuracy

ATB